metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Valaciclovir en el tratamiento de la primoinfección por el virus del herpes gen...
Journal Information
Vol. 19. Issue 1.
Pages 15-18 (January 2001)
Share
Share
Download PDF
More article options
Vol. 19. Issue 1.
Pages 15-18 (January 2001)
Full text access
Valaciclovir en el tratamiento de la primoinfección por el virus del herpes genital: estudio comparativo
Visits
13295
Ángel García, Juan Antonio Sánchez, Ignacio García, Juan Luis Lanchares
Departamento de Obstetricia y Ginecología. Facultad de Medicna
Silvia García1,a
a Facultad de Farmacia. Salamanca
This item has received
Article information
Fundamentos

Conocer la eficacia terapéutica del tratamiento en el herpes genital de dos fármacos: aciclovir y valaciclovir.

Métodos

Se incluyeron en el estudio 142 pacientes con diagnóstico de primoinfección clínica por herpes genital. Se distribuyeron en dos grupos iguales de 71 pacientes cada uno. La distribución en ambos grupos fue aleatoria para recibir una de las siguientes pautas de tratamiento: aciclovir 200 mg por vía oral cada 5 horas durante 7 días, o valaciclovir 500 mg por vía oral cada 12 horas durante 7 días, valorándose la respuesta objetiva y subjetiva al tratamiento.

Resultados

El síntoma predominante fue el dolor (45% y 46,4%), seguido del ardor o sensación de quemazón. La lesión más frecuente en ambos grupos fueron las vesículas (39,4% y 46,4%). En el análisis de la respuesta al tratamiento, tanto en relación con los síntomas como en las lesiones, se pudo apreciar que no existen diferencias significativas en las pacientes tratadas en ambos grupos (p=0,3). Los efectos adversos comunicados por las pacientes tratadas fueron escasos y similares en los dos grupos.

Conclusiones

Ambos fármacos son adecuados para el tratamiento del herpes genital. La ventaja observada con el valaciclovir es la comodidad de dosificación y la eficacia de cumplimentar el tratamiento.

Palabras clave:
Acyclovir
Valaciclovir
herpes genital
Bases

To know the therapeutic efficiency in the genital herpes of two drugs: acyclovir and valaciclovir.

Methods

There were included in the study 142 patients with diagnostic of clinic first episode by genital herpes in two equal groups of 71 patients each one. The distribution in both groups was random to receive one of the following treatment standards: acyclovir 200 mg by verbal each 5 hours, during 7 days; valaciclovir: 500 mg by verbal each 12 hours during 7 days being valued objetive and subjetive response to the treatment.

Results

The prevailing sympton was the pain (45% and 46.4%), followed by the warmth or burning sensation. The most frecuent injury in both groups were the bladdres (39.4% and 46.4%). The analysis response to the treatment in relationship to the symptons as well as in the injuries it could be apreciated that there are not significant differences in the patients treated in both groups (p=0,3). The adverse effect comunicated by the discussed patients were scarce and similar in both groups.

Conclusions

Both drugs are suitable for the treatment of the genital herpes. The adavantage abserved with the valaciclovir is the dosing comfort and the facility of complimenting the treatment.

Key words:
Acyclovir
Valaciclovir
genital herpes
Full text is only aviable in PDF
Bibliografía
[1.]
I. Quan.
Investigation on the incidencia of genital herpes in different professional groups in Qindao.
Chung Hua Lius Tsa Chih, 14 (1993), pp. 262-265
[2.]
G.J. Mertz.
Herpes simplex virus.
pp. 65
[3.]
R. Patel, N.J. Bodsworth, P. Woolley, S. Saari, J. Gibb, J. Robinsisn.
Valaciclovir for the supression of the recurrente genital HVS infection: A placebo controlled study of once therapy.
Genitourin, 73 (1997), pp. 105-109
[4.]
W.C. Reeves, L. Correy, M.G. Adams, R. Vontver, K. Holmes.
Risk of recurrence after first episodes of genital herpes. Relations to VHS type and antibody response.
N Engl J Med, 305 (1981), pp. 315-319
[5.]
J. Barberi Daste, R. Viraben, J. Icart.
Viroses et cancer de la vulva.
Rev Franc Ginecol Obst, 82 (1987), pp. 583-585
[6.]
S. Costa, J. Rotola, P. Terzano, M.G. Poggi, D. Di-Luca.
Search for herpes simplex virus 2 and human papillomavirus genetic expression in vulvar neoplasia.
J Rep Med, 35 (1990), pp. 1.108-1.112
[7.]
J. Bornstein, E. Ben-Porath, M. Nizari, Y. Satinger.
Evaluation of monoclonal antibody-based enzyme inmunoassay for early detection of herpes simplex virus genital infection.
ISR J Med Sci, 29 (1993), pp. 445-448
[8.]
C.G. Prober.
Herpatic vaginitis.
Clin Obst Ginecol, 36 (1993), pp. 177-178
[9.]
D.M. Koelle, J. Benedetti, A. Langenberg, L. Corey.
Asyntomatic reactivation of herpes, simplex virus in women after the first episode of genital herpes.
Ann Inter Med, 116 (1992), pp. 433-437
[10.]
M.L. Maccato, R.H. Kaufman.
Herpes genitalis.
Dermatol Clin, 9 (1992), pp. 433-437
[11.]
T.C. Burnette, P. de Miranda.
Metabolic disposition of the aciclovir Prodrugs valaciclovir in the rat.
Drug Metab Dispos, 3 (1992), pp. 157-164
[12.]
G. De Palo.
Panamericana,, (1992),
[13.]
F.A. Alrabiah, S.L. Sacks.
New antiherpesvirus agents. Their targets and therapeutic potential.
Drugs, 52 (1996), pp. 17-32
[14.]
R. Brugha, K. Keersmaekers, A. Renton, A. Meheus.
Genital herpes infection A review.
Int J Epidemiol, 26 (1997), pp. 698-709
[15.]
K. Beutner.
Valaciclovir a review of its antiviral activity pharmacokinetic properties and clinical efficacy.
Ant Resear, 28 (1995), pp. 181-290
[16.]
A. Wald, L. Corey, R. Cone, A. Hobson, G. Davis, J. Zeh.
Frequent genital herpes simplex virus 2 shedding in inmunocompetent women. Effect of acyclovir treatment.
J Clin Inv, 99 (1997), pp. 1.092-1.097
[17.]
R. Patel, F.M. Cowan, S.E. Barton.
Avisinng patients with genital herpes.
Brit Med J, 314 (1997), pp. 85-86
[18.]
S.E. Barton, P.E. Munday, R.J. Patel.
Asyntomatic shedding of herpes simplex virus from the genital tract: Uncertainly and its consequences for patient manegement. The herpes simplex virus advisory Panel.
Int J Std Aids, 7 (1996), pp. 229-232
[19.]
A. Wald, J. Zeh, G. Barnum, L.G. Davis, L. Corey.
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.
Ann Intern Med, 124 (1996), pp. 8-15
[20.]
P. Brocklehurst, T. Roberts.
Should acyclovir prophylaxis be use in late pregnancy in women with recurrent genital herpes infection? How to use a clinical decisión analisis.
Obstet Gynecol, 73 (1997), pp. 314-319
[21.]
A.G. Randolph, R.M. Hartshorn, A.E. Washington.
Acyclovir profilaxis in late pregnancy to prevent neonatal herpes: A const-effectiveness analysis.
Obstet Gynecol, 88 (1996), pp. 603-610
[22.]
S. Tyring, J. Douglas, L. Corey, S. Spruance.
A randomized, placebo-controlled comparison oral valaciclovir and acyclovir in inmunocompetent patients with recurrent genital herpes infections.
Arch Dermatol, 134 (1998), pp. 185
[23.]
C. Posavad, M.D. Koelle, M. Shaughnessy, L. Corey.
Severe genital herpes infections in HIV infected individuals with impaired herpes simplex virusspecific CD8+ cytotoxic T lymphocyte responses.
Proc Natl Acad Sci, 94 (1997), pp. 10.289-10.294
[24.]
N.C. Perry, D. Faulds.
Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infection.
Drugs, 52 (1996), pp. 754-772
[25.]
K. Fife, R. Barbarash, T. Rudolph, B. De Gregorio, R. Roth.
Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an International multicenter double-blind, randomized clinical trial. The valaciclovir international herpes simplex virus stugy group.
Sex Trasm Dis, 24 (1997), pp. 481-486
[26.]
R. Patel, T. Bodsworth, P. Woohey, B. Peters, G. Vejlsgaard, S. Saari.
Valaciclovir for the suppresion of genital VSH infection: A placebo controlled study group.
Genitourin Med, 73 (1997), pp. 105-109
[27.]
C. Perry, D. Faulds.
Valaciclovir. A review of its antiviral activity pharmacokinetic properties and therapeutic efficacy in herpes virus infections.
Drugs, 52 (1996), pp. 754-772
[28.]
A. Wagstaff, D. Faulds, K. Goa.
Acyclovir, a rea praisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.
Drugs, 47 (1994), pp. 153-205
[29.]
R. Whitley, J. Gnaan.
Acyclovir a decade later.
N Engl J Med, 327 (1992), pp. 782-789
[30.]
E. Acosta, C. Fletcher.
Valaciclovir.
Ann, Farmacol, 31 (1997), pp. 185-191
[31.]
M.S. Weller, R. Blum, M. Doucette, T. Burnette, D. Cederberg.
Pharmacokinetics of the acyclovir pro-drug valaciclovir, after escalating single and multiple-dose administration to normal volunteers.
Clin Pharmacol Therap, 54 (1993), pp. 595-609
[32.]
K. Beutner.
Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and clinical efficacy.
Antiv Researcch, 28 (1995), pp. 281-290
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos